| Dr Morris K Patteson Jr, MD | |
|
187 Private Road 4060, Lampasas, TX 76550-4071 | |
| (512) 556-3621 | |
| (512) 556-6594 |
| Full Name | Dr Morris K Patteson Jr |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 50 Years |
| Location | 187 Private Road 4060, Lampasas, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609858232 | NPI | - | NPPES |
| 080149495 | Other | TX | MEDICARE RAILROAD |
| 132325502 | Medicaid | TX | |
| 90046 | Other | TX | SCOTT & WHITE |
| 118137 | Other | TX | SUPERIOR |
| 89Y901 | Other | TX | BLUE CROSS/BLUE SHIELD |
| 121173100 | Other | TX | FIRST CARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | E2779 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tmc Provider Group Pllc | 6305149121 | 113 |
News Archive
Today, the American Society of Anesthesiologists announced their participation in a government-led effort to address the opioid epidemic, part of ASA's continued focus on patient safety and ongoing work to promote the safe use of prescription opioids. ASA is joined by a number of public and private sector partners in the efforts, which are being announced today by President Obama in Charleston, West Virginia.
In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Creighton University Medical Center has selected ProVation® MD software for Cardiology procedure documentation and coding. The software will be used to document and code catheterization cases at The Cardiac Center of Creighton University.
Angiotech Pharmaceuticals, Inc. today announced that in connection with its previously announced creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada), it and certain of its subsidiaries filed with the Supreme Court of British Columbia the Second Amended and Restated CCAA Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Entity Name | Tmc Provider Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053784660 PECOS PAC ID: 6305149121 Enrollment ID: O20160127002626 |
News Archive
Today, the American Society of Anesthesiologists announced their participation in a government-led effort to address the opioid epidemic, part of ASA's continued focus on patient safety and ongoing work to promote the safe use of prescription opioids. ASA is joined by a number of public and private sector partners in the efforts, which are being announced today by President Obama in Charleston, West Virginia.
In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Creighton University Medical Center has selected ProVation® MD software for Cardiology procedure documentation and coding. The software will be used to document and code catheterization cases at The Cardiac Center of Creighton University.
Angiotech Pharmaceuticals, Inc. today announced that in connection with its previously announced creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada), it and certain of its subsidiaries filed with the Supreme Court of British Columbia the Second Amended and Restated CCAA Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Entity Name | Adventhealth Family Medicine Rural Health Clinics, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861050569 PECOS PAC ID: 8628308533 Enrollment ID: O20190919000410 |
News Archive
Today, the American Society of Anesthesiologists announced their participation in a government-led effort to address the opioid epidemic, part of ASA's continued focus on patient safety and ongoing work to promote the safe use of prescription opioids. ASA is joined by a number of public and private sector partners in the efforts, which are being announced today by President Obama in Charleston, West Virginia.
In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Creighton University Medical Center has selected ProVation® MD software for Cardiology procedure documentation and coding. The software will be used to document and code catheterization cases at The Cardiac Center of Creighton University.
Angiotech Pharmaceuticals, Inc. today announced that in connection with its previously announced creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada), it and certain of its subsidiaries filed with the Supreme Court of British Columbia the Second Amended and Restated CCAA Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Morris K Patteson Jr, MD 207 W Avenue E, Lampasas, TX 76550-1820 Ph: (512) 556-3621 | Dr Morris K Patteson Jr, MD 187 Private Road 4060, Lampasas, TX 76550-4071 Ph: (512) 556-3621 |
News Archive
Today, the American Society of Anesthesiologists announced their participation in a government-led effort to address the opioid epidemic, part of ASA's continued focus on patient safety and ongoing work to promote the safe use of prescription opioids. ASA is joined by a number of public and private sector partners in the efforts, which are being announced today by President Obama in Charleston, West Virginia.
In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19.
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Creighton University Medical Center has selected ProVation® MD software for Cardiology procedure documentation and coding. The software will be used to document and code catheterization cases at The Cardiac Center of Creighton University.
Angiotech Pharmaceuticals, Inc. today announced that in connection with its previously announced creditor protection proceedings under the Companies' Creditors Arrangement Act (Canada), it and certain of its subsidiaries filed with the Supreme Court of British Columbia the Second Amended and Restated CCAA Plan of Compromise or Arrangement concerning, affecting and involving the Angiotech Entities.
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug-one with no known medical potential-to a schedule IV drug such as prescription sleep aids, but with tighter control.
› Verified 5 days ago
Dr. Raymond Gebhart Spaw, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1205 Central Texas Expy, Lampasas, TX 76550 Phone: 512-556-5362 Fax: 512-556-8004 | |
Dr. Mark S. Lane, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 187 Pr 4060, Lampasas, TX 76550 Phone: 512-556-3621 Fax: 512-556-6594 | |
Dr. Thomas Karl Kerley, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 602 N Key Ave, Lampasas, TX 76550 Phone: 512-556-3682 | |
Dr. Stephen Robert Vogel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 187 Pr 4060, Lampasas, TX 76550 Phone: 512-556-3621 Fax: 512-556-4080 | |
Dr. James E. Cain Iii, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 187 Pr 4060, Lampasas, TX 76550 Phone: 512-556-3621 Fax: 512-556-6594 | |
Reagan Duncan, APRN Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 187 Pr 4060, Lampasas, TX 76550 Phone: 512-556-3621 |